Cargando…

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis

Background: Sodium–glucose cotransporter 2 (SGLT2), also known as solute carrier family 5 member 2 (SLC5A2), is a promising target for a new class of drugs primarily established as kidney-targeting, effective glucose-lowering agents used in diabetes mellitus (DM) patients. Increasing evidence indica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wicik, Zofia, Nowak, Anna, Jarosz-Popek, Joanna, Wolska, Marta, Eyileten, Ceren, Siller-Matula, Jolanta M., von Lewinski, Dirk, Sourij, Harald, Filipiak‬, Krzysztof J., Postuła, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421436/ https://www.ncbi.nlm.nih.gov/pubmed/36046822 http://dx.doi.org/10.3389/fphar.2022.901340

Ejemplares similares

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review
por: Pordzik, Justyna, et al.
Publicado: (2019)

MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics
por: Jakubik, Daniel, et al.
Publicado: (2021)

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
por: Czajka, Pamela, et al.
Publicado: (2021)

Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study
por: Eyileten, Ceren, et al.
Publicado: (2022)

Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023)

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors
por: Wicik, Zofia, et al.
Publicado: (2020)

Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome
por: Eyileten, Ceren, et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review
por: Wolska, Marta, et al.
Publicado: (2020)

Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease
por: Gager, Gloria M., et al.
Publicado: (2022)

MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise—A Comprehensive Review
por: Soplinska, Aleksandra, et al.
Publicado: (2020)

Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19
por: Eyileten, Ceren, et al.
Publicado: (2022)

The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke
por: Eyileten, Ceren, et al.
Publicado: (2020)

Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
por: Gager, Gloria M., et al.
Publicado: (2023)

MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
por: Pordzik, Justyna, et al.
Publicado: (2021)

MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke—A Comprehensive Review and Bioinformatic Analysis
por: Eyileten, Ceren, et al.
Publicado: (2018)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
por: Eyileten, Ceren, et al.
Publicado: (2020)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023)

Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
por: Ostrowska, Małgorzata, et al.
Publicado: (2019)

The Importance of Non-Coding RNAs in Neurodegenerative Processes of Diabetes-Related Molecular Pathways
por: Jarosz-Popek, Joanna, et al.
Publicado: (2020)

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
por: Benedikt, Martin, et al.
Publicado: (2023)

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Bioresorbable Vascular Scaffolds—Dead End or Still a Rough Diamond?
por: Jeżewski, Mateusz P., et al.
Publicado: (2019)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
por: Schernthaner, Guntram, et al.
Publicado: (2019)

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Role of P2Y Receptors in Platelet Extracellular Vesicle Release
por: Gąsecka, Aleksandra, et al.
Publicado: (2020)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Altered Circulating MicroRNA Profiles After Endurance Training: A Cohort Study of Ultramarathon Runners
por: Eyileten, Ceren, et al.
Publicado: (2022)

Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications
por: Szwed, Piotr, et al.
Publicado: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients Admitted to Intensive Care Units with and without Diabetes
por: Aziz, Faisal, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ivearg6b2gvnlaa0vkjnbm9k2i